Document is current

Article History

Accepted: 10 February 2025

First Online: 4 March 2025

Declarations

:

: Financial support was provided by Janssen Scientific Affairs, LLC, a Johnson & Johnson company.

: DBM reports consulting/advisory roles for Adaptive Biotechnologies, Adicet, AlloGene, Janssen, Juno-Celgene-BMS, Kite-Gilead, Miltenyi Biotech, Novartis, Pharmacyclics LLC, an AbbVie Company, Precision Bioscience, and Takeda; and reports research funding from 2seventy bio, Adaptive Biotechnologies, Adicet Bio, AlloGene, Pharmacyclics LLC, an AbbVie Company, Genentech, Kite-Gilead, Miltenyi Biotech, Novartis, and Roche. PAR reports consulting/advisory roles for AbbVie, ADC Therapeutics, BeiGene, BMS, CVS Caremark, Genmab, Intellia Therapeutics, Janssen, Kite-Gilead, Nektar Therapeutics, Novartis, Nurix Therapeutics, Pharmacyclics LLC, an AbbVie Company, and Sana Biotechnology; and reports research funding from BMS, Calibr, CRISPR Therapeutics, Fate Therapeutics, Kite-Gilead, MorphoSys, Nkarta, Novartis, Roche, Tessa Therapeutics, and Xencor. AB reports employment and stock ownership at Janssen. JCC reports consulting roles for AstraZeneca, BeiGene, BMS, GenMab, Kite-Gilead, and Novartis; reports research funding from AstraZeneca, Janssen, and Kite-Gilead; and reports receiving honoraria from AstraZeneca, BeiGene, Janssen, and Lilly. SJS reports consulting/advisory roles for AbbVie, AstraZeneca, BeiGene, BioNTech, Caribou Biosciences, Genmab, Kite-Gilead, Legend Biotech, Novartis, and viTToria Biotherapeutics; and reports receiving honoraria from Janssen and Novartis.

: Not applicable.

: Not applicable.

: Not applicable.

: No new data were generated or analyzed in support of this research.

: Not applicable.

: All authors contributed equally to manuscript conceptualization, writing, editing, and reviewing.